A detailed history of Simplex Trading, LLC transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 4,056 shares of CUE stock, worth $4,056. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,056
Holding current value
$4,056
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$0.45 - $1.08 $1,825 - $4,380
4,056 New
4,056 $3,000
Q1 2024

Apr 25, 2024

BUY
$1.77 - $3.09 $16,869 - $29,450
9,531 New
9,531 $18,000
Q3 2023

Nov 01, 2023

BUY
$2.23 - $4.69 $49,766 - $104,666
22,317 New
22,317 $51,000
Q1 2023

Apr 27, 2023

BUY
$2.41 - $3.74 $27,922 - $43,331
11,586 New
11,586 $41,000
Q3 2022

Nov 04, 2022

SELL
$2.23 - $3.37 $3,166 - $4,785
-1,420 Reduced 7.97%
16,400 $36,000
Q2 2022

Aug 03, 2022

BUY
$2.49 - $5.92 $37,357 - $88,817
15,003 Added 532.59%
17,820 $44,000
Q1 2022

May 02, 2022

SELL
$4.41 - $12.28 $38,446 - $107,057
-8,718 Reduced 75.58%
2,817 $13,000
Q4 2021

Feb 23, 2022

BUY
$10.86 - $17.85 $44,786 - $73,613
4,124 Added 55.65%
11,535 $130,000
Q3 2021

Oct 28, 2021

BUY
$10.06 - $15.3 $6,036 - $9,180
600 Added 8.81%
7,411 $90,000
Q2 2021

Aug 12, 2021

SELL
$10.9 - $14.53 $33,899 - $45,188
-3,110 Reduced 31.35%
6,811 $79,000
Q1 2021

Apr 26, 2021

BUY
$11.2 - $16.09 $111,115 - $159,628
9,921 New
9,921 $121,000
Q3 2020

Oct 14, 2020

SELL
$15.05 - $23.54 $6,712 - $10,498
-446 Closed
0 $0
Q2 2020

Jul 13, 2020

SELL
$12.7 - $30.73 $6,832 - $16,532
-538 Reduced 54.67%
446 $0
Q1 2020

Apr 29, 2020

BUY
$9.85 - $22.27 $9,692 - $21,913
984 New
984 $13,000

Others Institutions Holding CUE

About Cue Biopharma, Inc.


  • Ticker CUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,381,700
  • Market Cap $35.4M
  • Description
  • Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...
More about CUE
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.